What can healthcare leaders learn from Mylan? 3 key points to consider in crises

Intense criticism has clouded above Mylan for increasing EpiPen’s price by more than 450 percent since 2004. In response, the pharmaceutical company announced it will offer a $300 generic alterative.

Advertisement

Health policy analyst Paul Keckley, PhD, offers three key lessons other healthcare organizations best heed from the Mylan controversy, according to Hospitals & Health Networks.

 

Here are three key points:

 

1. Healthcare doesn’t understand the meaning of “secrets.” From patients who are quick to discuss their experiences to employees who don’t hesitate to expand on their company cultures, the inner workings of just about anything will eventually come to light in this industry.

 

2. Company boards run the show, and can just as easily destroy a company as they can make a company. Therefore, boards must remember to guide a company in the direction balanced by “profit and social purpose,” and offer a transparent view of pricing strategies to both those inside and outside the company.

 

3. A CEO is the face of a company, especially in times of crisis, and must present an even-tempered, trustworthy demeanor. If they fail to do so, the company’s longevity and reputation may very well be decided in a moment.

 

More articles on practice management:
Public supports limiting shift hours for first-year residents — 4 things to know
ASC-based outpatient, hospital-based inpatient total shoulder arthroplasty prove equally safe: 5 study insights
FDA holds 2-day public hearing on stem cell regulation: 5 notes

Advertisement

Next Up in Practice Management

Advertisement

Comments are closed.